# Polymers Based on PLA from Synthesis Using D,L-Lactic Acid (or Racemic Lactide) and Some Biomedical Applications: A Short Review

**Authors:** Juliene Oliveira Campos de França, Deborah da Silva Valadares, Mateus Freitas Paiva, Sílvia Cláudia Loureiro Dias, José Alves Dias

PMC · DOI: 10.3390/polym14122317 · Polymers · 2022-06-08

## TL;DR

This review discusses the synthesis and biomedical uses of PLA polymers made from D,L-lactic acid, emphasizing sustainability and degradability.

## Contribution

The paper highlights the use of cheaper, racemic monomers for sustainable PLA production and their biomedical applications.

## Key findings

- PLA can be synthesized using D,L-lactic acid or racemic lactide for cost-effective and sustainable processes.
- PDLLA and its derivatives show promise in biomedical applications due to their degradability and compatibility.
- Specific composting conditions are necessary for the complete degradation of PLA-based materials.

## Abstract

Poly(lactic acid) (PLA) is an important polymer that is based on renewable biomass resources. Because of environmental issues, more renewable sources for polymers synthesis have been sought for industrial purposes. In this sense, cheaper monomers should be used to facilitate better utilization of less valuable chemicals and therefore granting more sustainable processes. Some points are raised about the need to study the total degradability of any PLA, which may require specific composting conditions (e.g., temperature, type of microorganism, adequate humidity and aerobic environment). Polymerization processes to produce PLA are presented with an emphasis on D,L-lactic acid (or rac-lactide) as the reactant monomer. The syntheses involving homogeneous and heterogeneous catalytic processes to produce poly(D,L-Lactic acid) (PDLLA) are also addressed. Additionally, the production of blends, copolymers, and composites with PDLLA are also presented exemplifying different preparation methods. Some general applications of these materials mostly dedicated to the biomedical area over the last 10–15 years will be pointed out.

## Linked entities

- **Chemicals:** D,L-lactic acid (PubChem CID 612), rac-lactide (PubChem CID 7272), poly(lactic acid) (PubChem CID 61503), PLA (PubChem CID 1018)

## Full-text entities

- **Genes:** ELN (elastin) [NCBI Gene 2006] {aka ADCL1, SVAS, WBS, WS}, LYZ (lysozyme) [NCBI Gene 4069] {aka AMYLD5, LYZF1, LZM}
- **Diseases:** endocrine disruptors (MESH:D004700), thrombosis (MESH:D013927), ROP (MESH:D012303), brain tumors (MESH:D001932), inflammatory (MESH:D007249), DM (MESH:D003920), hemolysis (MESH:D006461), carcinogenic effect (MESH:D065606), diabetic foot ulcers (MESH:D017719), tumor (MESH:D009369), ACS (MESH:D000168), glioma (MESH:D005910), coronary artery disease (MESH:D003324), cytotoxicity (MESH:D064420), coronavirus (MESH:D018352), conjunctivitis (MESH:D003231)
- **Species:** Staphylococcus aureus (species) [taxon 1280], Niallia circulans (species) [taxon 1397], Homo sapiens (human, species) [taxon 9606], Leptospira sp. AB (species) [taxon 103236], Lactobacillus helveticus (species) [taxon 1587], Oryctolagus cuniculus (domestic rabbit, species) [taxon 9986], Bacteria Latreille et al. 1825 (Bacteria stick insect, genus) [taxon 629395], PX clade (clade) [taxon 569578], Cupriavidus necator (species) [taxon 106590]
- **Mutations:** C at 70, 3D by X, C) to 133

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC9229942/full.md

## Figures

15 figures with captions in the complete paper: https://tomesphere.com/paper/PMC9229942/full.md

## References

159 references — full list in the complete paper: https://tomesphere.com/paper/PMC9229942/full.md

---
Source: https://tomesphere.com/paper/PMC9229942